Welcome to our dedicated page for Protagonist Ther news (Ticker: PTGX), a resource for investors and traders seeking the latest updates and insights on Protagonist Ther stock.
Protagonist Therapeutics (PTGX) is a clinical-stage biopharmaceutical leader developing oral peptide therapies for inflammatory and hematologic conditions. This news hub provides investors and researchers with essential updates on clinical trials, regulatory milestones, and strategic partnerships.
Access timely announcements about PTGX's innovative constrained peptide platform and pipeline candidates like icotrokinra (IL-23 antagonist) and rusfertide (hepcidin mimetic). Our curated collection includes press releases on trial results, FDA communications, and collaborations with industry leaders including Johnson & Johnson.
Key updates cover therapeutic advancements for psoriasis, ulcerative colitis, and polycythemia vera. Bookmark this page to monitor Protagonist's progress in transforming biologic-like treatments into oral formulations while maintaining competitive positioning through proprietary drug discovery methods.
Protagonist Therapeutics (NASDAQ:PTGX) announced the pricing of its underwritten public offering of 5 million shares at $20.00 per share, totaling $100 million in gross proceeds. The offering is expected to close around April 10, 2023. Proceeds will fund continued clinical development of rusfertide and general corporate purposes. Underwriters have the option to purchase an additional 750,000 shares. Major underwriters include J.P. Morgan, Jefferies, and Piper Sandler. The registration statement for the offering was effective as of August 16, 2022.
FAQ
What is the current stock price of Protagonist Ther (PTGX)?
What is the market cap of Protagonist Ther (PTGX)?
